Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study.

BMJ Neurol Open · 2024 · PMC11191820 · PMID 38912173

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep = 0.07so close (0.05 < p ≤ 0.1)

Notably, only IgA levels during dose 4 and dose 5 did not reach statistical significance (p = 0.07 and p = 0.06, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.